Literature DB >> 2350327

Antiarrhythmic and antinecrotic effects of yohimbine stereoisomers in rats during coronary occlusion and reperfusion.

W Bernauer1.   

Abstract

In pentobarbital-anesthetized rats the left coronary artery was ligated for 5 or 30 min and then opened for reperfusion of the ischemic myocardial area. Twelve min prior to the coronary occlusion yohimbine stereoisomers, namely corynanthine and rauwolscine, or saline solution were given intravenously. In the saline controls both ischemia and reperfusion provoked severe tachyarrhythmias with ventricular fibrillation in 37.5% or 54.6%, respectively. Using corynanthine and rauwolscine a highly significant antiarrhythmic effect was observed. Corynanthine completely prevented ventricular fibrillation and delayed significantly the development of myocardial necrosis. The factors likely underlying the antiarrhythmic and antinecrotic effects are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2350327     DOI: 10.1007/bf01906966

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  27 in total

1.  Pre- and postsynaptic effects of yohimbine stereoisomers on noradrenergic transmission in the pulmonary artery of the rabbit.

Authors:  R Weitzell; T Tanaka; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

2.  Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats.

Authors:  D J Sheridan; P A Penkoske; B E Sobel; P B Corr
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

3.  Yohimbine blockade of ionic channels in myocardial cells.

Authors:  J Azuma; S Vogel; I Josephson; N Sperelakis
Journal:  Eur J Pharmacol       Date:  1978-09-15       Impact factor: 4.432

4.  Effects of yohimbine, rauwolscine and corynanthine on contractions and calcium fluxes induced by depolarization and prostaglandin F2 alpha in rat aorta.

Authors:  T Godfraind; R C Miller; J Socrates Lima
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

5.  Release of endogenous catecholamines in the ischemic myocardium of the rat. Part B: Effect of sympathetic nerve stimulation.

Authors:  A M Dart; A Schömig; R Dietz; E Mayer; W Kübler
Journal:  Circ Res       Date:  1984-11       Impact factor: 17.367

6.  Effects of ganglionic blockade on noradrenaline release and cell injury in the acutely ischemic rat myocardium.

Authors:  T Abrahamsson; O Almgren; S Holmgren
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jul-Aug       Impact factor: 3.105

7.  The effect of beta-adrenoceptor blocking agents on evolving myocardial necrosis in coronary ligated rats with and without reperfusion.

Authors:  W Bernauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-01       Impact factor: 3.000

8.  Effect of alpha-adrenoceptor antagonists (phentolamine, nicergoline and prazosin) on reperfusion arrhythmias and noradrenaline release in perfused rat heart.

Authors:  J Bralet; J Didier; D Moreau; L H Opie; L Rochette
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

9.  Effects of glucocorticosteroids in rats with acute myocardial infarction.

Authors:  W Bernauer
Journal:  Arch Int Pharmacodyn Ther       Date:  1980-03

10.  The effect of ethanol on arrhythmias and myocardial necrosis in rats with coronary occlusion and reperfusion.

Authors:  W Bernauer
Journal:  Eur J Pharmacol       Date:  1986-07-31       Impact factor: 4.432

View more
  2 in total

1.  Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan in rabbits.

Authors:  J C Roegel; N Yannoulis; W De Jong; L Monassier; J Feldman; P Bousquet
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

2.  Post-ischemic release of nucleosides and oxypurines in isolated rat hearts. Possible involvement of ventricular fibrillation.

Authors:  W Bernauer
Journal:  Basic Res Cardiol       Date:  1991 Jan-Feb       Impact factor: 17.165

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.